Bromodiphenhydramine

Summary

Bromodiphenhydramine (CHEMBL1201245) is an approved small-molecule antimicrobial agent (ATC R06AA01); indicated across 1 condition including allergic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AA01
• Indications: 1 condition
• Chemistry: 334.2 Da · C17H20BrNO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201245
Name	Bromodiphenhydramine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2444
ChEBI	CHEBI:59177
ATC	R06AA01
Molecular formula	C17H20BrNO
Molecular weight	334.2
InChIKey	NUNIWXHYABYXKF-UHFFFAOYSA-N

SMILES: CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br

IUPAC name: 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine

ChEBI definition: A tertiary amino compound that is the 4-bromobenzhydryl ether of 2-(dimethylamino)ethanol. An antihistamine with antimicrobial properties, it is used in the control of cutaneous allergies.

Pharmacological roles (ChEBI): antimicrobial agent, muscarinic antagonist, H1-receptor antagonist.

Also known as: Bromazina, Bromazine, Deserol, Histabromamine, Neo-benadryl, SID170465292, BROMODIPHENHYDRAMINE, bromazine

Parent form; salt/anhydrous children: CHEMBL1200967

Patent coverage: 734 distinct patent families (2,518 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Mu-type opioid receptor, D(3) dopamine receptor.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A4	6.68	AC50	207.4	nM	CHEMBL_ACT_25151701
SLC6A3	6.12	AC50	756.7	nM	CHEMBL_ACT_25125333
CHRM2	5.85	AC50	1421	nM	CHEMBL_ACT_25196110
CHRM1	5.83	AC50	1490	nM	CHEMBL_ACT_25210530
DRD3	5.57	AC50	2676	nM	CHEMBL_ACT_25194886
DRD1	5.53	AC50	2953	nM	CHEMBL_ACT_25115584
SLC6A2	5.38	AC50	4216	nM	CHEMBL_ACT_25146374
ADRA2A	5.08	AC50	8381	nM	CHEMBL_ACT_25156803

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).